No Data
YaoKang Biological (688046.SH): There is currently no research on brain nerve signal acquisition, decoding, control, and feedback.
On January 17, Gelonghui reported that Yaokang Biotechnology (688046.SH) stated on its investor interaction platform that the company currently has no research in areas such as brain neural signal acquisition, decoding, control, and feedback. However, the company has a rich reserve of experimental animal models for neurological diseases and related pathway-targeted gene knockout mouse models. Additionally, the company can provide diagnostic testing, pathological testing, and behavioral testing services that simulate/compare with corresponding clinical patients, which can be offered to downstream customers for related research.
YaoKang Bio (688046.SH): Provides gene editing models such as B6-hGLP-1R and B6-hGIPR.
On January 17, Gelonghui reported that Yaokang Biotechnology (688046.SH) stated on the investor interaction platform that the company has a rich reserve of models in the field of metabolism. In addition to providing classic obesity models such as DIO and db for weight loss drug research, it also offers Gene Editing models such as B6-hGLP-1R and B6-hGIPR. Furthermore, the company provides customers with related pharmacological and efficacy experimental outsourcing services to support downstream clients in drug development.
Market Cool On GemPharmatech Co., Ltd.'s (SHSE:688046) Earnings
Yakkang Biotech: Yakang Biotech Report for the Third Quarter of 2024
Yakkang Biotech Report for the Third Quarter of 2024
Yao Kang Biology (688046.SH): Achieved net income of 98.2144 million yuan in the first three quarters.
Pharmaron (688046.SH) announced on October 30th that the company achieved revenue of 0.51 billion yuan in the first three quarters of 2024, a year-on-year increase of 12.13%; the net income attributable to the shareholders of the listed company was 98.2144 million yuan, a year-on-year decrease of 16.57%, with a basic earnings per share of 0.24 yuan.
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking